Ranibizumab: Treatment of age-related macular degeneration humanized monoclonal anti-VEGF antibody angiogenesis inhibitor

Drugs of the Future

Volumn 28, Issue 6, 2003, Pages 541-545

  Sorbera, L A ^a   Leeson, P A ^a   Bayes M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; HUMANIZED VASCULOTROPIN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; SQUALAMINE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ADULT; ANTERIOR EYE CHAMBER; ANTIGEN BINDING; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; INFLAMMATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RABBIT; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; STEADY STATE; SUBRETINAL NEOVASCULARIZATION;

EID: 0141746067     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.06.738510     Document Type: Article

References (37)

1. Prous Science Drug R&D Backgrounders: Macular degeneration (online publication). Updated May 22, 2003.
2. Chopdar, A., Chakravarthy, U., Verma, D. Age related macular degeneration. BMJ - Br Med J 2003, 326: 485-8.
3. Dunaief, J.L., Dentchev, T., Ying, G.S., Milam, A.H. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002, 120: 1435-42.
4. Gottlieb, J.L. Age-related macular degeneration. JAMA - J Am Med Assoc 2002, 288: 2233-6.
5. Husain, D., Ambati, B., Adamis, A.P., Miller, J.W. Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am 2002, 15: 87-91.
6. Hyman, L., Neborsky, R. Risk factors for age-related macular degeneration: An update. Curr Opin Ophthalmol 2002, 13: 171-5.
7. Klaver, C.C., Kliffen, M., van Duijn, C.M., Hofman, A., Cruts, M., Grobbee, D.E., van Broeckhoven, C., de Jong, P.T. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998, 63: 200-6.
8. Simonelli, F., Margaglione, M., Testa, F., Cappucci, G., Manitto, M.P., Brancato, R., Rinaldi, E. Apolipoprotein E polymorphisms in age-related macular degeneration in an Italian population. Ophthalmic Res 2001, 33: 325-8.
9. Yates, J.R., Moore, A.T. Genetic susceptibility to age related macular degeneration. J Med Genet 2000, 37: 83-7.
10. Treatment of age-related macular degeneration with photodynamic therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials -TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999, 117: 1329-45.
11. Schmidt-Erfurth, U., Miller, J.W., Sickenberg, M. et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999, 117: 1177-87.
12. Ferrara, N., Bunting, S. Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 1996, 5: 35-44.
13. Kvanta, A., Algvere, P.V., Berglin, L., Seregard, S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996, 37: 1929-34.
14. Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B., Hinton, D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Visual Sci 1996, 37: 855-68.
15. Aiello, L.P., Avery, R.L., Arrigg, RG. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New Engl J Med 1994, 331: 1480-7.
16. Adamis, A.P., Shima, D.T., Tolentino, M.J., Gragoudas, E.S., Ferrara, N., Folkman, J., D'Amore, P.A., Miller, J.W. Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114: 66-71.
17. Lowe, J., Araujo, J., Palma, M., Wang, Y., Gaudreault, J., Yang, J., Yu, N., Fei, D. RhuFab 2 inhibits VEGF-isoforms-stimulated HUVEC proliferation. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 1828.
18. Gaudreault, J., Reich, M., Arata, A., Rusit, J., Pelletier, N., Shiu, V. Ocular pharmacokinetics and antipermeability effect of rhuFab V2 in animals. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 3942.
19. O'Neill, C.A., Miller, P.E., Christian, B.J., Beyer, J.C., Bentley, E., VerHoeve, J.N., Nork, T.M., Leedle, R.A., Dubielzig, R.R., Albert, D.M. 26-Week intravitreal injection toxicity study with rhuFab VEGF in cynomolgus monkeys with an 8-week recovery. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 3929.
20. Krzystolik, M.G., Afshari, M.A., Adamis, A.P., Gaudreault, J., Gragoudas, E.S., Michaud, N.A., Li, W., Connolly, E., O'Neill, C.A., Miller, J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002, 120: 338-46.
21. Gauthier, D., Husain, D., Kim, I.K., Ezra, E., Tsilimbaris, M.K., Connolly, E., Lane, A.M., Gragoudas, E.S., O'Neill, C.A., Miller, J.W. Safety and efficacy of intravitreal injection of rhuFab VEGF in combination with verteporfin PDT on experimental choroidal neovascularization. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 566.
22. Hsei, V., Siguenza, P., Ralph, P., Baughmann, S., Gaudreault, J. Preclinical pharmacokinetic comparison of two rhuMAb VEGF molecules. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 14-18, New Orleans) 1999, Abst.
23. Gaudreault, J., Escandon, E., Maruoka, M., Reich, M., Li, D., Hsei, V. Vitreal pharmacokinetics of rhuFab V2 in rabbits using a non-invasive method. Annu Meet Assoc Res Vision Ophthalmol (May 5-10, Fort Lauderdale) 2002, Abst 2801.
24. Gaudreault, J., Webb, W., Van Hoy, M. et al. Pharmacokinetics and retinal distribution of AMD rhuFab V2 after intravitreal administration in rabbits. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 14-18, New Orleans) 1999, Abst.
25. Gaudreault, J., Fei, D., Suboc, P., Chan, P., Nelson, J., Lappin, P., Hartmangruber, M., Rusit, J., O'Neill, C., Hsei, V. Ocular pharmacokinetics (PK) of rhuFab V2 following intravitreal (ITV) administration in cynomolgus monkeys. Annu Meet Assoc Res Vision Ophthalmol (April 29-May 4, Fort Lauderdale) 2001, Abst.
26. Blumenkranz, M., Rosenfeld, P.J., Miller, J.W., Haller, J., Fish, G., Lobes, L., Singerman, L., Greene, W.L., Reimann, J. Safety of rhuFab V2, an anti-VEGF antibody fragment, as a single intravitreal injection in subjects with neovascular age-related macular degeneration. Annu Meet Assoc Res Vision Ophthalmol (April 29-May 4, Fort Lauderdale) 2001, Abst.
27. McCluskey, E.R. RhuFab V2, an antiangiogenic Fab antibody fragment that binds VEGF, is being investigated as an intravitreal injection in subjects with neovascular age-related macular degeneration. 4th Int Symp Ocular Pharmacol Pharm (Feb 28-March 3, Seville) 2002, Addendum.
28. Rosenfeld, P.J., Villate, N., Feuer, W.J., Puliafito, C.A., McCluskey, E.R. RhuFab V2 (anti-VEGF antibody fragment) in neovascular AMD: Safety, tolerability, and efficacy of multiple, escalating dose intravitreal injections. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 970.
29. Puliafito, C.A., McCluskey, E.R. Optical coherence tomographic (OCT) findings following treatment of choroidal neovascularization with rhuFabV2. 35th Annu Meet Retina Soc (Sept 28-Oct 2, San Francisco) 2002, Abst.
30. Heier, J.S., Sy, J.R., McCluskey, E.R. RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections. Annu Meet Assoc Res Vision Ophthalmol (May 4-9, Fort Lauderdale) 2003, Abst 972.
31. 2003 First Quarter Report. Genentech Web Site, April 2003.
32. Safety & efficacy study of rhuFab V2 in combination with verteporfin for treatment of age-related macular degeneration. ClinicalTrials.gov June 2, 2003.
33. Efficacy and safety study of rhuFab V2 (ranibizumab) to treat age-related macular degeneration. ClinicalTrials.gov June 2, 2003.
34. Safety and efficacy study of rhuFAb V2 (ranibizumab) to treat age-related macular degeneration. ClinicalTrials.gov June 2, 2003.
35. Heier, J.S., Sy, J.P., McCluskey, E.R. RhuFabV2 (anti-VEGF antibody) for treatment of exudative AMD. 35th Annu Meet Retina Soc (Sept 28-Oct 2, San Francisco) 2002, Abst.
36. Husain, D., Kim, I., Gauthier, D. et al. Safety and efficacy of intravitreai injection of rhuFab VEGF V2 in combination with verteporfin PDT on experimental choroidal neovascularization. 35th Annu Meet Retina Soc (Sept 28-Oct 2, San Francisco) 2002, Abst.
37. Heier, J.S., Greene, W.L. RhuFab V2 (an anti-VEGF antibody fragment) in neovascular AMD: Safety and tolerability of multiple intravitreal injections. Annu Meet Assoc Res Vision Ophthalmol (May 5-10, Fort Lauderdale) 2002, Abst 2520.